Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has received an average rating of “Hold” from the six brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $3.00.
Separately, Rodman & Renshaw began coverage on shares of Nektar Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $2.00 target price on the stock.
View Our Latest Stock Report on Nektar Therapeutics
Insider Activity at Nektar Therapeutics
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in shares of Nektar Therapeutics by 2,822.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 551,535 shares of the biopharmaceutical company’s stock worth $684,000 after buying an additional 532,663 shares in the last quarter. Values First Advisors Inc. bought a new stake in Nektar Therapeutics in the second quarter valued at $56,000. SG Americas Securities LLC raised its stake in Nektar Therapeutics by 63.0% during the second quarter. SG Americas Securities LLC now owns 73,352 shares of the biopharmaceutical company’s stock worth $91,000 after acquiring an additional 28,338 shares in the last quarter. Lynx1 Capital Management LP lifted its holdings in shares of Nektar Therapeutics by 7.2% during the first quarter. Lynx1 Capital Management LP now owns 2,068,842 shares of the biopharmaceutical company’s stock valued at $1,933,000 after acquiring an additional 139,644 shares during the period. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Nektar Therapeutics in the 1st quarter valued at $63,000. Institutional investors own 75.88% of the company’s stock.
Nektar Therapeutics Stock Performance
NKTR opened at $1.36 on Tuesday. The company has a market cap of $250.27 million, a PE ratio of -1.48 and a beta of 0.66. The stock has a 50-day moving average of $1.33 and a 200-day moving average of $1.13. Nektar Therapeutics has a 52-week low of $0.41 and a 52-week high of $1.93.
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.03. Nektar Therapeutics had a negative return on equity of 107.31% and a negative net margin of 195.02%. The firm had revenue of $21.64 million during the quarter, compared to analyst estimates of $14.91 million. During the same period in the previous year, the company earned ($0.25) EPS. On average, research analysts predict that Nektar Therapeutics will post -0.84 earnings per share for the current year.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
Featured Stories
- Five stocks we like better than Nektar Therapeutics
- Stock Market Upgrades: What Are They?
- Survey: Top 175 Fittest Retirement Locations in America
- Breakout Stocks: What They Are and How to Identify Them
- Kimberly-Clark Stock Dips and a Buying Opportunity Emerges
- What is a Death Cross in Stocks?
- Leading Gold Stock Shines With Q2 2024 Earnings Release
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.